FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2050652275> ?p ?o ?g. }

• W2050652275 endingPage "4593" @default.
• W2050652275 startingPage "4593" @default.
• W2050652275 abstract "Abstract The leading challenge in pancreatic cancer treatment is inability to deliver sufficient amounts of therapeutic agents into cancer cells due to the presence of extensive tumor stroma. Increasing evidence shows that pancreatic tumor microenvironment promotes proliferation, metastasis, and chemoresistance of the cancer cells. Urokinase plasminogen activator receptor (uPAR) is highly expressed in pancreatic tumor cells and tumor stroma but is not found in the normal pancreas. Therapeutic agents targeting to uPAR may offer a means to break down the tumor stromal barrier and enhance drug delivery into cancer cells. In this study, we engineered a near infrared dye NIR-830 labeled amino-terminal fragment (ATF) of mouse uPA conjugated magnetic iron oxide nanoparticles (IONP) carrying chemotherapy drug cisplatin (Cis) without or with PEG-coating (ATF-IONP-Cis ATF-PEG-IONP-Cis). To determine the effect of PEG-coating on non-specific uptake of the IONPs by enriched macrophages in the peritoneal cavity and its consequent effect on targeted delivery of the theranostic IONPs, we established a mouse pancreatic tumor model derived from the PANC02 cell line with simultaneous carrying a subcutaneous and an orthotopic tumor. First, we examined the best delivery method for this animal tumor model and found that the i.p. delivery of mouse uPAR targeted ATF-PEG-IONPs resulted in stronger optical signal in the orthotopic cancers with much lesser signals in the liver compared that of the i.v. delivery. Next, the effects of the i.p. delivery of the ATF-IONP-Cis, ATF-PEG-IONP-Cis, and non-targeted ATF-IONP-Cis were evaluated in the mouse pancreatic cancer model. We found that i.p. delivery of 5 mg/kg of Cisplatin equivalent ATF-IONP-Cis or ATF-PEG IONP-Cis every 3 day for 4 injections significantly inhibited tumor growth (Control vs ATF-PEG-IONP-cis: p=0.008; ATF-IONP-Cis: p=0.016). It seemed that PEG-coating didn't affect the inhibitory effects of ATF-IONP-Cis nanoparticles on tumor growth. However, free cisplatin and non-targeted-IONP-Cis treated groups didn't show significant anti-tumor effects. We also observed that the mice treated with ATF-IONP-Cis had much less amounts of ascites (average 0.5ml/mouse) compared to the mice treated with free cisplatin (an average of 5 ml/mouse). Additionally, markedly systemic toxicity effect was seen in the mice treated conventional cisplatin but this was not observed in the mice treated with ATF-IONP-cis. We further confirmed targeted delivery of ATF-IONP-cis into the tumor using Prussian blue staining on frozen tissue sections and chemical analysis to quantify amount of IONPs in tumor tissues. Taken together, the ATF-PEG-IONP-Cis theranostic nanoparticles and the i.p. delivery approach developed in this study have great potential for the development of novel targeted and image-guided treatment of pancreatic cancer Citation Format: Ning Gao, Erica Bozeman, Weiping Qian, Charles Staley, Andrew Wang, Hui Mao, Lily Yang. Targeted therapy of pancreatic cancer by intraperitoneal delivery of uPAR-targeted theranostic nanoparticles. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4593. doi:10.1158/1538-7445.AM2014-4593" @default.
• W2050652275 created "2016-06-24" @default.
• W2050652275 creator A5003443072 @default.
• W2050652275 creator A5014218695 @default.
• W2050652275 creator A5041917469 @default.
• W2050652275 creator A5061915588 @default.
• W2050652275 creator A5068714594 @default.
• W2050652275 creator A5069432493 @default.
• W2050652275 creator A5083411426 @default.
• W2050652275 date "2014-10-01" @default.
• W2050652275 modified "2023-09-23" @default.
• W2050652275 title "Abstract 4593: Targeted therapy of pancreatic cancer by intraperitoneal delivery of uPAR-targeted theranostic nanoparticles" @default.
• W2050652275 doi "https://doi.org/10.1158/1538-7445.am2014-4593" @default.
• W2050652275 hasPublicationYear "2014" @default.
• W2050652275 type Work @default.
• W2050652275 sameAs 2050652275 @default.
• W2050652275 citedByCount "1" @default.
• W2050652275 countsByYear W20506522752022 @default.
• W2050652275 crossrefType "journal-article" @default.
• W2050652275 hasAuthorship W2050652275A5003443072 @default.
• W2050652275 hasAuthorship W2050652275A5014218695 @default.
• W2050652275 hasAuthorship W2050652275A5041917469 @default.
• W2050652275 hasAuthorship W2050652275A5061915588 @default.
• W2050652275 hasAuthorship W2050652275A5068714594 @default.
• W2050652275 hasAuthorship W2050652275A5069432493 @default.
• W2050652275 hasAuthorship W2050652275A5083411426 @default.
• W2050652275 hasConcept C121608353 @default.
• W2050652275 hasConcept C126322002 @default.
• W2050652275 hasConcept C126511603 @default.
• W2050652275 hasConcept C142724271 @default.
• W2050652275 hasConcept C16930146 @default.
• W2050652275 hasConcept C178790620 @default.
• W2050652275 hasConcept C185592680 @default.
• W2050652275 hasConcept C204232928 @default.
• W2050652275 hasConcept C2776107976 @default.
• W2050652275 hasConcept C2777996000 @default.
• W2050652275 hasConcept C2779013556 @default.
• W2050652275 hasConcept C2779679481 @default.
• W2050652275 hasConcept C2779820397 @default.
• W2050652275 hasConcept C2780210213 @default.
• W2050652275 hasConcept C2781230642 @default.
• W2050652275 hasConcept C3020616263 @default.
• W2050652275 hasConcept C502942594 @default.
• W2050652275 hasConcept C52124034 @default.
• W2050652275 hasConcept C56219504 @default.
• W2050652275 hasConcept C71924100 @default.
• W2050652275 hasConcept C96232424 @default.
• W2050652275 hasConceptScore W2050652275C121608353 @default.
• W2050652275 hasConceptScore W2050652275C126322002 @default.
• W2050652275 hasConceptScore W2050652275C126511603 @default.
• W2050652275 hasConceptScore W2050652275C142724271 @default.
• W2050652275 hasConceptScore W2050652275C16930146 @default.
• W2050652275 hasConceptScore W2050652275C178790620 @default.
• W2050652275 hasConceptScore W2050652275C185592680 @default.
• W2050652275 hasConceptScore W2050652275C204232928 @default.
• W2050652275 hasConceptScore W2050652275C2776107976 @default.
• W2050652275 hasConceptScore W2050652275C2777996000 @default.
• W2050652275 hasConceptScore W2050652275C2779013556 @default.
• W2050652275 hasConceptScore W2050652275C2779679481 @default.
• W2050652275 hasConceptScore W2050652275C2779820397 @default.
• W2050652275 hasConceptScore W2050652275C2780210213 @default.
• W2050652275 hasConceptScore W2050652275C2781230642 @default.
• W2050652275 hasConceptScore W2050652275C3020616263 @default.
• W2050652275 hasConceptScore W2050652275C502942594 @default.
• W2050652275 hasConceptScore W2050652275C52124034 @default.
• W2050652275 hasConceptScore W2050652275C56219504 @default.
• W2050652275 hasConceptScore W2050652275C71924100 @default.
• W2050652275 hasConceptScore W2050652275C96232424 @default.
• W2050652275 hasIssue "19_Supplement" @default.
• W2050652275 hasLocation W20506522751 @default.
• W2050652275 hasOpenAccess W2050652275 @default.
• W2050652275 hasPrimaryLocation W20506522751 @default.
• W2050652275 hasRelatedWork W2005812634 @default.
• W2050652275 hasRelatedWork W2029712941 @default.
• W2050652275 hasRelatedWork W2050652275 @default.
• W2050652275 hasRelatedWork W2084400792 @default.
• W2050652275 hasRelatedWork W2191316874 @default.
• W2050652275 hasRelatedWork W2346074809 @default.
• W2050652275 hasRelatedWork W2567212605 @default.
• W2050652275 hasRelatedWork W2883081969 @default.
• W2050652275 hasRelatedWork W3033174144 @default.
• W2050652275 hasRelatedWork W4220755377 @default.
• W2050652275 hasVolume "74" @default.
• W2050652275 isParatext "false" @default.
• W2050652275 isRetracted "false" @default.
• W2050652275 magId "2050652275" @default.
• W2050652275 workType "article" @default.